Posted by Michael Wonder on 28 Feb 2017
NICE publishes draft guidance on Keytruda
28 February 2017 - The Department of Health has asked NICE to produce guidance on using pembrolizumab in the NHS in England for non-small-cell lung cancer.
Pembrolizumab is not recommended, within its marketing authorisation, for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults whose tumours express PD-L1 with at least a 50% tumour proportion score and have no epidermal growth factor receptor- or anaplastic lymphoma kinase-positive mutations.
The use of pembrolizumab on the NHS will be considered at a second appraisal committee meeting on 29 March 2017.
